ticlopidine has been researched along with Symptom Cluster in 94 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " It was the aim of the present study to assess whether the response to aspirin and clopidogrel may be influenced by the 807 C/T polymorphism of the glycoprotein Ia (GpIa) gene in patients with non-ST elevation acute coronary syndrome (NSTE ACS)." | 9.12 | Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. ( Alessi, MC; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J; Romero-Barra, M; Saut, N, 2007) |
| " Approximately 13,000 patients with moderate to high-risk ACS undergoing PCI (9500 unstable angina/non-ST-segment elevation myocardial infarction [MI], 3500 ST-segment elevation MI) will be randomized to prasugrel 60 mg loading dose followed by 10 mg daily or clopidogrel 300 mg loading dose followed by 75 mg daily for up to 15 months." | 9.12 | Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Riesmeyer, J; Warmke, JW; Weerakkody, G; Winters, KJ; Wiviott, SD, 2006) |
| "To assess effects of clopidogrel loading dose and long term therapy in addition to standard treatment on death, re-infarction, recurrence of angina and bleedings rate in patients with ST segment elevation acute coronary syndrome." | 9.12 | [Effectiveness and safety of clopidogrel bisulfate in complex therapy of patients with acute coronary syndrome with ST segment elevation]. ( Giliarov, MIu; Malova, EV; Novikova, NA; Sulimov, VA; Syrkin, AL, 2006) |
| " The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes." | 9.12 | Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007) |
| "Although clopidogrel and aspirin (dual therapy, DT) are used for acute coronary syndrome (ACS), sometimes treatment with warfarin (triple therapy, TT) is required." | 9.12 | Aspirin, warfarin and a thienopyridine for acute coronary syndromes. ( Behar, S; Gottlieb, S; Hammerman, H; Hasdai, D; Hod, H; Iakobishvili, Z; Konstantino, Y; Porter, A; Sandach, A; Zahger, D, 2006) |
| "Platelet inhibition with clopidogrel in patients for up to one year after presentation with an acute coronary syndrome is both effective and cost-effective." | 9.11 | Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. ( Caro, J; Culler, S; Gabriel, S; Lamy, A; Mahoney, EM; Weintraub, WS; Yuan, Y; Yusuf, S, 2005) |
| "In patients with NSTE-ACS undergoing early invasive strategy, the adjunctive administration of upstream tirofiban did not reduce the peak values and the cumulative release of myocardial necrosis markers, compared with aspirin, heparin, and clopidogrel given on admission and associated with selective use of abciximab just before PCI." | 9.11 | Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea ( Badia, T; Bellandi, F; Dabizzi, RP; De Servi, S; Leoncini, M; Maioli, M; Politi, A; Toso, A, 2005) |
| "Effects of thienopyridines ticlopidine (TIC) and clopidogrel (CL) on hemostasis in patients (pts) with non-ST-elevation acute coronary syndromes (NSTEACS) have not been compared." | 9.11 | [Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome]. ( Averkov, OV; Gratsianskiĭ, NA; Slavina, NN, 2005) |
| "Whether thienopyridines (ticlopidine or clopidogrel) produce similar effects on fibrinolysis in patients with non ST elevation acute coronary syndrome (NSTEACS) was not well elucidated." | 9.10 | [Non ST elevation acute coronary syndrome. Parameters of fibrinolysis during short term use of ticlopidine or clopidogrel]. ( Averkov, OV; Dobrovol'skiĭ, AB; Gratsianskiĭ, NA; Slavina, NN, 2003) |
| "We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 9.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
| "After acute coronary syndromes, the beneficial effect of aspirin plus clopidogrel (A+C) or aspirin plus dose-adjusted warfarin (A+W) compared with aspirin alone is well established." | 8.84 | Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. ( Agostoni, P; Andreotti, F; Crea, F; Porto, I; Testa, L; Trotta, G; Zoccai, GB, 2007) |
| "Clopidogrel was shown to have added benefits to aspirin in patients with acute coronary syndromes without ST-segment elevation in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial." | 8.82 | CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction. ( Doggrell, SA, 2005) |
| "Recent studies have suggested that low-dose aspirin has preserved benefit with less bleeding compared with standard-dose aspirin when given with or without clopidogrel in patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACSs)." | 7.74 | Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. ( Cannon, CP; Gibler, WB; Milford-Beland, S; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tickoo, S, 2007) |
| "(i) to determine the proportion of "low-responders" or "resistants" patients during coronary syndrome (ii) to identify determinants of interindividual variability response to clopidogrel (iii) to compare aggregometry and VASP phosphorylation measured by flow cytometry." | 7.74 | [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation]. ( Bareiss, P; Chauvin, M; Desprez, D; Faure, A; Grunebaum, L; Jesel, L; Morel, O; Ohlmann, P; Roul, G; Viellard, C, 2007) |
| "We sought to characterize patterns of clopidogrel use before coronary artery bypass grafting (CABG) and examine the drug's impact on risks for postoperative transfusions among patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS)." | 7.73 | Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. ( Cannon, CP; Ferguson, TB; Gibler, WB; Mehta, RH; Mulgund, J; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC, 2006) |
| "Clopidogrel given for up to 1 year in patients undergoing PCI after presentation with acute coronary syndromes is a highly cost-effective treatment strategy." | 7.73 | Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. ( Caro, J; Chen, R; Culler, S; Gabriel, S; Jackson, J; Lamy, A; Mahoney, EM; Mehta, S; Weintraub, WS; Yuan, Y; Yusuf, S, 2006) |
| " 178 consecutive patients admitted for acute coronary syndrome received 250 mg of intravenous aspirin together with either a loading dose of 300 mg of clopidogrel (n = 104) or 600 mg (n = 74) administered 12 to 24 hours prior to coronary angiography." | 7.73 | [Beneficial effect of a loading dose of 600 mg of clopidogrel on platelet parameters in patients admitted for acute coronary syndrome]. ( Alessi, MC; Bonnet, JL; Carvajal, J; Cuisset, T; Frère, C; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Saidi, LN, 2006) |
| "Results from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study showed that clopidogrel plus aspirin, compared to aspirin alone, reduced cardiovascular events (death, myocardial infarction, and stroke) in patients with acute coronary syndromes (ACS)." | 7.73 | A cost analysis in patients with acute coronary syndrome using clopidogrel in addition to aspirin in a Hong Kong public hospital. ( Chan, WK; Lee, KK; Lee, VW, 2006) |
| "Clopidogrel added to aspirin improved outcomes after hospitalization in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial, regardless of in-hospital treatment approach." | 7.73 | Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. ( Bhatt, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Harrington, RA; Mulgund, J; Newby, LK; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC; Tricoci, P, 2006) |
| "We report a case of a severe hypersensitivity syndrome reaction to clopidogrel that resolved with dechallenge and recurred on rechallenge." | 7.73 | Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia. ( Begg, EJ; Bridgman, P; Doogue, MP, 2005) |
| "In clinical practice, we found no significant difference between atorvastatin therapy or other statin therapies in the clinical outcomes of patients with acute coronary syndromes receiving clopidogrel therapy." | 7.72 | Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. ( Bossaller, C; Gitt, AK; Heer, T; Juenger, C; Limbourg, P; Meisenzahl, C; Schiele, R; Senges, J; Wienbergen, H, 2003) |
| "In a large, randomized, placebo-controlled trial in centers that use a conservative approach to acute coronary syndromes, the antiplatelet drug clopidogrel (Plavix) decreased the rate of the combined end point of cardiovascular death, nonfatal myocardial infarction, or stroke by 20% in patients presenting with acute coronary syndromes without ST-segment elevation." | 7.71 | The CURE trial: using clopidogrel in acute coronary syndromes without ST-segment elevation. ( Bhatt, DL; Gerschutz, GP, 2002) |
| " The CURE trial shows that clopidogrel in addition to aspirin achieves this double goal, with a 20% relative risk reduction in the primary composite endpoint of cardiovascular death, myocardial infarction or stroke in the first 30 days." | 7.71 | [Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial]. ( Valentín, V, 2001) |
| "Aspirin has proven benefits in primary and secondary prevention of coronary artery disease." | 6.42 | Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. ( Badimon, JJ; Bhatt, DL; Corti, R; Francis, GS; Fuster, V; Jneid, H, 2003) |
| "Kounis syndrome is the concurrence of acute coronary syndrome with allergic reactions, such as anaphylaxis or anaphylactoid reactions." | 5.42 | An Extraordinary Case Associated with an Allergic Reaction to Clopidogrel: Coronary Artery Spasm or Kounis Syndrome? ( Bin, H; Liping, Z; Qiming, F, 2015) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 5.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "The consumption coagulopathy was successfully controlled by continuous intravenous infusion of heparin (17,000 I." | 5.29 | [Kasabach-Merritt syndrome. Intraoperative heparin therapy with follow-up combination therapy of heparin and ticlopidine for the control of intravascular coagulation]. ( Blatter, G; Hanselmann, C; Korte, W; Schmid, L; Ziegler, JP, 1993) |
| "A total of 55 patients with a history of thrombosis and SPS phenotype were prospectively studied before and after treatment with aspirin and/or clopidogrel." | 5.20 | Primary thrombophilia in México X: a prospective study of the treatment of the sticky platelet syndrome. ( García-Chavez, J; Hernández-Reyes, J; Rosales-Padrón, J; Ruiz-Arguelles, A; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Vargas-Espinosa, J; Velázquez-Sánchez-de-Cima, S; Zamora-Ortiz, G, 2015) |
| " Approximately 13,000 patients with moderate to high-risk ACS undergoing PCI (9500 unstable angina/non-ST-segment elevation myocardial infarction [MI], 3500 ST-segment elevation MI) will be randomized to prasugrel 60 mg loading dose followed by 10 mg daily or clopidogrel 300 mg loading dose followed by 75 mg daily for up to 15 months." | 5.12 | Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Riesmeyer, J; Warmke, JW; Weerakkody, G; Winters, KJ; Wiviott, SD, 2006) |
| " It was the aim of the present study to assess whether the response to aspirin and clopidogrel may be influenced by the 807 C/T polymorphism of the glycoprotein Ia (GpIa) gene in patients with non-ST elevation acute coronary syndrome (NSTE ACS)." | 5.12 | Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. ( Alessi, MC; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J; Romero-Barra, M; Saut, N, 2007) |
| "Although clopidogrel and aspirin (dual therapy, DT) are used for acute coronary syndrome (ACS), sometimes treatment with warfarin (triple therapy, TT) is required." | 5.12 | Aspirin, warfarin and a thienopyridine for acute coronary syndromes. ( Behar, S; Gottlieb, S; Hammerman, H; Hasdai, D; Hod, H; Iakobishvili, Z; Konstantino, Y; Porter, A; Sandach, A; Zahger, D, 2006) |
| " The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes." | 5.12 | Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007) |
| "To assess effects of clopidogrel loading dose and long term therapy in addition to standard treatment on death, re-infarction, recurrence of angina and bleedings rate in patients with ST segment elevation acute coronary syndrome." | 5.12 | [Effectiveness and safety of clopidogrel bisulfate in complex therapy of patients with acute coronary syndrome with ST segment elevation]. ( Giliarov, MIu; Malova, EV; Novikova, NA; Sulimov, VA; Syrkin, AL, 2006) |
| "In patients with NSTE-ACS undergoing early invasive strategy, the adjunctive administration of upstream tirofiban did not reduce the peak values and the cumulative release of myocardial necrosis markers, compared with aspirin, heparin, and clopidogrel given on admission and associated with selective use of abciximab just before PCI." | 5.11 | Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea ( Badia, T; Bellandi, F; Dabizzi, RP; De Servi, S; Leoncini, M; Maioli, M; Politi, A; Toso, A, 2005) |
| "Effects of thienopyridines ticlopidine (TIC) and clopidogrel (CL) on hemostasis in patients (pts) with non-ST-elevation acute coronary syndromes (NSTEACS) have not been compared." | 5.11 | [Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome]. ( Averkov, OV; Gratsianskiĭ, NA; Slavina, NN, 2005) |
| "To study efficacy of treating patients with acute coronary syndrome (ACS) without ST segment elevation (STSE) with platelet dysaggregation drugs (aspirin, cardiomagnil, clopidogrel)." | 5.11 | [Dysaggregants effect of platelet aggregation in patients with non-ST segment elevation acute coronary syndrome]. ( Kapilevich, NA; Kisteneva, IV; Markov, VA; Novitskiĭ, VV; Poponina, TM, 2004) |
| "Platelet inhibition with clopidogrel in patients for up to one year after presentation with an acute coronary syndrome is both effective and cost-effective." | 5.11 | Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. ( Caro, J; Culler, S; Gabriel, S; Lamy, A; Mahoney, EM; Weintraub, WS; Yuan, Y; Yusuf, S, 2005) |
| "We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 5.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
| "Whether thienopyridines (ticlopidine or clopidogrel) produce similar effects on fibrinolysis in patients with non ST elevation acute coronary syndrome (NSTEACS) was not well elucidated." | 5.10 | [Non ST elevation acute coronary syndrome. Parameters of fibrinolysis during short term use of ticlopidine or clopidogrel]. ( Averkov, OV; Dobrovol'skiĭ, AB; Gratsianskiĭ, NA; Slavina, NN, 2003) |
| "After acute coronary syndromes, the beneficial effect of aspirin plus clopidogrel (A+C) or aspirin plus dose-adjusted warfarin (A+W) compared with aspirin alone is well established." | 4.84 | Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. ( Agostoni, P; Andreotti, F; Crea, F; Porto, I; Testa, L; Trotta, G; Zoccai, GB, 2007) |
| "Clopidogrel has demonstrated improved outcomes for patients with acute coronary syndromes in several large randomized controlled trials." | 4.84 | Clopidogrel: who, when, and how? ( Cannon, CP, 2007) |
| "Clopidogrel was shown to have added benefits to aspirin in patients with acute coronary syndromes without ST-segment elevation in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial." | 4.82 | CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction. ( Doggrell, SA, 2005) |
| " Beta-blockers, nitrates, and calcium-channel blockers are useful for antiischemic therapy in patients with acute coronary syndromes." | 4.81 | [Acute coronary syndromes: an update. I. Pathogenesis and drug therapy]. ( Auer, J; Berent, R; Eber, B; Maurer, E; Mayr, H; Weber, T, 2001) |
| "Rate of resistance to aspirin and clopidogrel was assessed in 44 patients with non ST elevation acute coronary syndrome." | 3.74 | [Resistance to antiplatelet drugs in patients with non ST elevation acute coronary syndrome]. ( Aĭnetdinova, DKh; Sulimov, VA; Udovichenko, AE, 2008) |
| "(i) to determine the proportion of "low-responders" or "resistants" patients during coronary syndrome (ii) to identify determinants of interindividual variability response to clopidogrel (iii) to compare aggregometry and VASP phosphorylation measured by flow cytometry." | 3.74 | [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation]. ( Bareiss, P; Chauvin, M; Desprez, D; Faure, A; Grunebaum, L; Jesel, L; Morel, O; Ohlmann, P; Roul, G; Viellard, C, 2007) |
| "Recent studies have suggested that low-dose aspirin has preserved benefit with less bleeding compared with standard-dose aspirin when given with or without clopidogrel in patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACSs)." | 3.74 | Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. ( Cannon, CP; Gibler, WB; Milford-Beland, S; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tickoo, S, 2007) |
| "High post-treatment platelet reactivity (HPPR=adenosine diphosphate [ADP] 10 microM-induced platelet aggregation >70%) identifies low responders to dual antiplatelet therapy with increased risk of recurrent cardiovascular (CV) events after stenting for non-ST elevation acute coronary syndromes (NSTE-ACS)." | 3.74 | High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. ( Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Lambert, M; Mielot, C; Morange, PE; Nait-Saidi, L; Quilici, J, 2007) |
| " We describe a case of very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment, which occurred just 2 weeks after its withdrawal, causing an acute coronary syndrome that was promptly resolved with an urgent invasive strategy." | 3.74 | Very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment after percutaneous coronary intervention. ( Bucciarelli-Ducci, C; Colantonio, R; Fedele, F; Mancone, M; Sangiorgi, GM; Sardella, G, 2007) |
| "Aspirin resistance is a well-documented laboratory finding, but the effects of clinical aspirin (ASA) failure on patients with acute coronary syndrome (ACS) have been debated." | 3.74 | Dual antiplatelet agent failure: a new syndrome or clinical nonentity? ( Armstrong, DF; Barnes, GD; Eagle, KA; Froehlich, JB; Gurm, HS; Kline-Rogers, E; Li, J; Vedre, A, 2007) |
| "We sought to characterize patterns of clopidogrel use before coronary artery bypass grafting (CABG) and examine the drug's impact on risks for postoperative transfusions among patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS)." | 3.73 | Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. ( Cannon, CP; Ferguson, TB; Gibler, WB; Mehta, RH; Mulgund, J; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC, 2006) |
| " 178 consecutive patients admitted for acute coronary syndrome received 250 mg of intravenous aspirin together with either a loading dose of 300 mg of clopidogrel (n = 104) or 600 mg (n = 74) administered 12 to 24 hours prior to coronary angiography." | 3.73 | [Beneficial effect of a loading dose of 600 mg of clopidogrel on platelet parameters in patients admitted for acute coronary syndrome]. ( Alessi, MC; Bonnet, JL; Carvajal, J; Cuisset, T; Frère, C; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Saidi, LN, 2006) |
| "Clopidogrel added to aspirin improved outcomes after hospitalization in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial, regardless of in-hospital treatment approach." | 3.73 | Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. ( Bhatt, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Harrington, RA; Mulgund, J; Newby, LK; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC; Tricoci, P, 2006) |
| "Results from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study showed that clopidogrel plus aspirin, compared to aspirin alone, reduced cardiovascular events (death, myocardial infarction, and stroke) in patients with acute coronary syndromes (ACS)." | 3.73 | A cost analysis in patients with acute coronary syndrome using clopidogrel in addition to aspirin in a Hong Kong public hospital. ( Chan, WK; Lee, KK; Lee, VW, 2006) |
| "We report a case of a severe hypersensitivity syndrome reaction to clopidogrel that resolved with dechallenge and recurred on rechallenge." | 3.73 | Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia. ( Begg, EJ; Bridgman, P; Doogue, MP, 2005) |
| "Clopidogrel given for up to 1 year in patients undergoing PCI after presentation with acute coronary syndromes is a highly cost-effective treatment strategy." | 3.73 | Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. ( Caro, J; Chen, R; Culler, S; Gabriel, S; Jackson, J; Lamy, A; Mahoney, EM; Mehta, S; Weintraub, WS; Yuan, Y; Yusuf, S, 2006) |
| "In clinical practice, we found no significant difference between atorvastatin therapy or other statin therapies in the clinical outcomes of patients with acute coronary syndromes receiving clopidogrel therapy." | 3.72 | Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. ( Bossaller, C; Gitt, AK; Heer, T; Juenger, C; Limbourg, P; Meisenzahl, C; Schiele, R; Senges, J; Wienbergen, H, 2003) |
| " The CURE trial shows that clopidogrel in addition to aspirin achieves this double goal, with a 20% relative risk reduction in the primary composite endpoint of cardiovascular death, myocardial infarction or stroke in the first 30 days." | 3.71 | [Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial]. ( Valentín, V, 2001) |
| "In a large, randomized, placebo-controlled trial in centers that use a conservative approach to acute coronary syndromes, the antiplatelet drug clopidogrel (Plavix) decreased the rate of the combined end point of cardiovascular death, nonfatal myocardial infarction, or stroke by 20% in patients presenting with acute coronary syndromes without ST-segment elevation." | 3.71 | The CURE trial: using clopidogrel in acute coronary syndromes without ST-segment elevation. ( Bhatt, DL; Gerschutz, GP, 2002) |
| "Atherothrombosis is a progressive and generalized pathologic process that affects the vascular system." | 2.44 | Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. ( Brown, MT; Kikano, GE, 2007) |
| "Aspirin has proven benefits in primary and secondary prevention of coronary artery disease." | 2.42 | Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. ( Badimon, JJ; Bhatt, DL; Corti, R; Francis, GS; Fuster, V; Jneid, H, 2003) |
| "Treatment with ticlopidine, a platelet-aggregation inhibitor (250 mg twice daily), was initiated and she has now been free of extracutaneous symptoms for 6 years." | 2.39 | [Malignant atrophic papulosis]. ( Aumiller, J; Kutzner, H; Ostendorf, PC; Saeger, W; Voigt, C, 1994) |
| "Kounis syndrome is the concurrence of acute coronary syndrome with allergic reactions, such as anaphylaxis or anaphylactoid reactions." | 1.42 | An Extraordinary Case Associated with an Allergic Reaction to Clopidogrel: Coronary Artery Spasm or Kounis Syndrome? ( Bin, H; Liping, Z; Qiming, F, 2015) |
| "Unilateral vertebral artery dissection has been described in fewer than 40% of cases of RCVS." | 1.39 | Reversible cerebral vasoconstriction syndrome and bilateral vertebral artery dissection presenting in a patient after cesarean section. ( Do, HM; Mitchell, LA; Santarelli, JG; Singh, IP, 2013) |
| "Although obesity is a known risk factor for coronary artery disease, its impact on the presentation, treatment, and outcome of patients with acute coronary syndromes (ACS) has not been well studied." | 1.33 | The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart A ( Boden, WE; Diercks, DB; Gibler, WB; Kirk, JD; Mulgund, J; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC, 2006) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 1.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "Susac's syndrome is a rare disorder characterized by the triad of microangiopathy of the brain and retina with hearing loss." | 1.31 | Susac's syndrome: beneficial effects of corticosteroid therapy in a Japanese case. ( Hashimoto, Y; Tashima, K; Uchino, M; Uyama, E; Yonehara, T, 2001) |
| "Kasabach-Merritt syndrome is an infrequent combination of a giant hemangioma and severe thrombocytopenia." | 1.30 | -Neonatal Kasabach-Merritt syndrome healed by complete surgical excision of the angioma-. ( Dupont, D; Golkar, A; Valla, JS; Velin, P, 1998) |
| "The consumption coagulopathy was successfully controlled by continuous intravenous infusion of heparin (17,000 I." | 1.29 | [Kasabach-Merritt syndrome. Intraoperative heparin therapy with follow-up combination therapy of heparin and ticlopidine for the control of intravascular coagulation]. ( Blatter, G; Hanselmann, C; Korte, W; Schmid, L; Ziegler, JP, 1993) |
| "Kasabach-Merritt syndrome is a combination of thrombocytopenia, intravascular coagulation, and a rapid increase in the size of an angioma." | 1.28 | [Kasabach-Merritt syndrome in children]. ( Andry, P; Bodemer, C; Brunelle, F; de Prost, Y; Hubert, P; Nihoul-Fékété, C; Sebag, G; Teillac-Hamel, D, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (6.38) | 18.2507 |
| 2000's | 80 (85.11) | 29.6817 |
| 2010's | 8 (8.51) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Velázquez-Sánchez-de-Cima, S | 1 |
| Zamora-Ortiz, G | 1 |
| Hernández-Reyes, J | 1 |
| Vargas-Espinosa, J | 1 |
| García-Chavez, J | 1 |
| Rosales-Padrón, J | 1 |
| Ruiz-Delgado, GJ | 1 |
| Ruiz-Arguelles, A | 1 |
| Ruiz-Argüelles, GJ | 1 |
| Liping, Z | 1 |
| Bin, H | 1 |
| Qiming, F | 1 |
| Yamada, E | 1 |
| Okada, S | 1 |
| Saito, T | 1 |
| Osaki, A | 1 |
| Ozawa, A | 1 |
| Yamada, M | 1 |
| Kinnear, N | 1 |
| Hennessey, DB | 1 |
| Douglass-Molloy, H | 1 |
| Jack, G | 1 |
| Aĭnetdinova, DKh | 1 |
| Udovichenko, AE | 1 |
| Sulimov, VA | 2 |
| Ponikowski, P | 1 |
| Ronco, C | 1 |
| Anker, SD | 1 |
| Naik, A | 1 |
| Mian, T | 1 |
| Abraham, A | 1 |
| Rajput, V | 1 |
| Stankovic, I | 1 |
| Vlahovic-Stipac, A | 1 |
| Ilic, I | 1 |
| Putnikovic, B | 1 |
| Neskovic, AN | 1 |
| Mitchell, LA | 1 |
| Santarelli, JG | 1 |
| Singh, IP | 1 |
| Do, HM | 1 |
| Otterstad, JE | 1 |
| Fox, KA | 3 |
| Hughes, K | 1 |
| Yusuf, S | 5 |
| Mehta, SR | 3 |
| Zhao, F | 2 |
| Gersh, BJ | 2 |
| Commerford, PJ | 2 |
| Blumenthal, M | 1 |
| Budaj, A | 1 |
| Wittlinger, T | 1 |
| Bartolozzi, JJ | 1 |
| Price, WF | 1 |
| Sauls, FC | 1 |
| Jneid, H | 1 |
| Bhatt, DL | 3 |
| Corti, R | 1 |
| Badimon, JJ | 1 |
| Fuster, V | 1 |
| Francis, GS | 1 |
| Schroeder, WS | 1 |
| Gandhi, PJ | 2 |
| Fries, R | 1 |
| Böhm, M | 1 |
| Genoni, M | 1 |
| Tavakoli, R | 1 |
| Hofer, C | 1 |
| Bertel, O | 1 |
| Turina, M | 1 |
| Wienbergen, H | 1 |
| Gitt, AK | 1 |
| Schiele, R | 1 |
| Juenger, C | 1 |
| Heer, T | 1 |
| Meisenzahl, C | 1 |
| Limbourg, P | 1 |
| Bossaller, C | 1 |
| Senges, J | 1 |
| Slavina, NN | 3 |
| Averkov, OV | 3 |
| Dobrovol'skiĭ, AB | 1 |
| Gratsianskiĭ, NA | 3 |
| Prasad, A | 1 |
| Mathew, V | 1 |
| Holmes, DR | 1 |
| Peters, RJ | 2 |
| Lewis, BS | 2 |
| Kopecky, SL | 1 |
| Diaz, R | 1 |
| Valentin, V | 2 |
| Phillips, EJ | 1 |
| Knowles, SR | 1 |
| Shear, NH | 1 |
| Roffi, M | 1 |
| Topol, EJ | 2 |
| Bennett, SK | 1 |
| Redberg, RF | 1 |
| Schwaab, B | 1 |
| Poponina, TM | 1 |
| Kapilevich, NA | 1 |
| Kisteneva, IV | 1 |
| Markov, VA | 1 |
| Novitskiĭ, VV | 1 |
| Rupprecht, HJ | 1 |
| Weintraub, WS | 2 |
| Mahoney, EM | 2 |
| Lamy, A | 2 |
| Culler, S | 2 |
| Yuan, Y | 2 |
| Caro, J | 2 |
| Gabriel, S | 2 |
| Elsässer, A | 1 |
| Nef, H | 1 |
| Möllmann, H | 1 |
| Hamm, CW | 1 |
| Doggrell, SA | 1 |
| Fahey, CD | 1 |
| Alberts, MJ | 1 |
| Bernstein, RA | 1 |
| Leoncini, M | 1 |
| Toso, A | 1 |
| Maioli, M | 1 |
| Bellandi, F | 1 |
| Badia, T | 1 |
| Politi, A | 1 |
| De Servi, S | 1 |
| Dabizzi, RP | 1 |
| Comert, A | 1 |
| Akgun, S | 1 |
| Civelek, A | 1 |
| Kavala, M | 1 |
| Sarigül, S | 1 |
| Yildirim, T | 1 |
| Arsan, S | 1 |
| Doogue, MP | 1 |
| Begg, EJ | 1 |
| Bridgman, P | 1 |
| Di Nisio, M | 1 |
| Bijsterveld, NR | 1 |
| Meijers, JC | 1 |
| Levi, M | 1 |
| Büller, HR | 1 |
| Konstantino, Y | 1 |
| Iakobishvili, Z | 1 |
| Porter, A | 1 |
| Sandach, A | 1 |
| Zahger, D | 1 |
| Hod, H | 1 |
| Hammerman, H | 1 |
| Gottlieb, S | 1 |
| Behar, S | 1 |
| Hasdai, D | 1 |
| Salam, AM | 1 |
| Al Suwaidi, J | 1 |
| Mehta, S | 1 |
| Jackson, J | 1 |
| Chen, R | 1 |
| Cuisset, T | 4 |
| Frere, C | 4 |
| Quilici, J | 4 |
| Barbou, F | 1 |
| Morange, PE | 4 |
| Hovasse, T | 1 |
| Bonnet, JL | 4 |
| Alessi, MC | 4 |
| Biondi-Zoccai, GG | 1 |
| Abbate, A | 1 |
| Agostoni, P | 2 |
| Valgimigli, M | 1 |
| Sangiorgi, GM | 2 |
| Heptinstall, S | 1 |
| Klaus, T | 1 |
| Ahrens, I | 1 |
| Bode, C | 2 |
| Galvani, M | 1 |
| Megalopoulos, A | 1 |
| Vasiliadis, K | 1 |
| Tsachalis, T | 1 |
| Tsalis, K | 1 |
| Blouhos, K | 1 |
| Alexandridou, S | 1 |
| Betsis, D | 1 |
| Casella, G | 1 |
| Greco, C | 1 |
| Maggioni, AP | 1 |
| Di Pasquale, G | 1 |
| Tricoci, P | 1 |
| Roe, MT | 4 |
| Mulgund, J | 3 |
| Newby, LK | 1 |
| Smith, SC | 3 |
| Pollack, CV | 4 |
| Fintel, DJ | 1 |
| Cannon, CP | 4 |
| Gibler, WB | 4 |
| Ohman, EM | 4 |
| Peterson, ED | 4 |
| Harrington, RA | 1 |
| Ikeda, U | 1 |
| Macdonald, J | 1 |
| Srinivasan, M | 1 |
| More, R | 1 |
| Diercks, DB | 1 |
| Kirk, JD | 1 |
| Boden, WE | 1 |
| Mehta, RH | 1 |
| Ferguson, TB | 1 |
| Giugliano, RP | 1 |
| Braunwald, E | 2 |
| Vavuranakis, M | 1 |
| Latsios, G | 1 |
| Aggelis, D | 1 |
| Bosinakou, I | 1 |
| Karambelas, I | 1 |
| Tousoulis, D | 1 |
| Toutouzas, K | 1 |
| Stefanadis, C | 1 |
| Malova, EV | 1 |
| Syrkin, AL | 1 |
| Giliarov, MIu | 1 |
| Novikova, NA | 1 |
| Heeg, B | 1 |
| van Gestel, A | 1 |
| Hout, Bv | 1 |
| Olsen, J | 1 |
| Haghfelt, TH | 1 |
| Wiviott, SD | 1 |
| Antman, EM | 1 |
| Gibson, CM | 1 |
| Montalescot, G | 1 |
| Riesmeyer, J | 1 |
| Weerakkody, G | 1 |
| Winters, KJ | 1 |
| Warmke, JW | 1 |
| McCabe, CH | 1 |
| Fuchs, I | 1 |
| Frossard, M | 1 |
| Spiel, A | 1 |
| Riedmüller, E | 1 |
| Laggner, AN | 1 |
| Jilma, B | 1 |
| Saidi, LN | 1 |
| Carvajal, J | 1 |
| Lambert, M | 3 |
| Mouret, JP | 1 |
| Ziegelstein, RC | 1 |
| Lee, VW | 1 |
| Chan, WK | 1 |
| Lee, KK | 1 |
| Radke, PW | 1 |
| Schunkert, H | 1 |
| Münzel, TF | 1 |
| Post, F | 1 |
| Cattaneo, M | 1 |
| Saut, N | 1 |
| Romero-Barra, M | 1 |
| Camoin, L | 1 |
| Juhan-Vague, I | 1 |
| Nait-Saidi, L | 1 |
| Mielot, C | 1 |
| Bali, L | 1 |
| Małek, ŁA | 1 |
| Spiewak, M | 1 |
| Filipiak, KJ | 1 |
| Grabowski, M | 1 |
| Szpotańska, M | 1 |
| Rosiak, M | 1 |
| Główczyńska, R | 1 |
| Imiela, T | 1 |
| Huczek, Z | 1 |
| Opolski, G | 1 |
| Silva, MA | 1 |
| Donovan, JL | 1 |
| Volturo, GA | 1 |
| Morel, O | 1 |
| Viellard, C | 1 |
| Faure, A | 1 |
| Jesel, L | 1 |
| Ohlmann, P | 1 |
| Desprez, D | 1 |
| Chauvin, M | 1 |
| Roul, G | 1 |
| Grunebaum, L | 1 |
| Bareiss, P | 1 |
| Keltai, M | 1 |
| Tonelli, M | 1 |
| Mann, JF | 1 |
| Sitkei, E | 1 |
| Hawken, S | 1 |
| Kikano, GE | 1 |
| Brown, MT | 1 |
| Tickoo, S | 1 |
| Milford-Beland, S | 1 |
| Testa, L | 1 |
| Zoccai, GB | 1 |
| Porto, I | 1 |
| Trotta, G | 1 |
| Andreotti, F | 1 |
| Crea, F | 1 |
| Sardella, G | 1 |
| Bucciarelli-Ducci, C | 1 |
| Mancone, M | 1 |
| Colantonio, R | 1 |
| Fedele, F | 1 |
| Barnes, GD | 1 |
| Li, J | 1 |
| Kline-Rogers, E | 1 |
| Vedre, A | 1 |
| Armstrong, DF | 1 |
| Froehlich, JB | 1 |
| Eagle, KA | 1 |
| Gurm, HS | 1 |
| Vyas, S | 1 |
| Roberti, I | 1 |
| McCarthy, C | 1 |
| Voigt, C | 1 |
| Aumiller, J | 1 |
| Saeger, W | 1 |
| Kutzner, H | 1 |
| Ostendorf, PC | 1 |
| Korte, W | 1 |
| Blatter, G | 1 |
| Ziegler, JP | 1 |
| Hanselmann, C | 1 |
| Schmid, L | 1 |
| Léauté-Labrèze, C | 1 |
| Bioulac-Sage, P | 1 |
| Labbé, L | 1 |
| Méraud, JP | 1 |
| Taïeb, A | 1 |
| Velin, P | 1 |
| Dupont, D | 1 |
| Golkar, A | 1 |
| Valla, JS | 1 |
| Yamaguchi, T | 1 |
| Nakamura, M | 1 |
| Mitsuo, K | 1 |
| Matsuda, K | 1 |
| Peter, K | 1 |
| Nordt, T | 1 |
| Tashima, K | 1 |
| Uyama, E | 1 |
| Hashimoto, Y | 1 |
| Yonehara, T | 1 |
| Uchino, M | 1 |
| Auer, J | 1 |
| Berent, R | 1 |
| Maurer, E | 1 |
| Mayr, H | 1 |
| Weber, T | 1 |
| Eber, B | 1 |
| Maseri, A | 1 |
| Cianflone, D | 1 |
| Margonato, A | 1 |
| Pizzetti, G | 1 |
| Berjón Reyero, J | 1 |
| Gerschutz, GP | 1 |
| Teillac-Hamel, D | 1 |
| Andry, P | 1 |
| Bodemer, C | 1 |
| Hubert, P | 1 |
| Sebag, G | 1 |
| Brunelle, F | 1 |
| Nihoul-Fékété, C | 1 |
| de Prost, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
27 reviews available for ticlopidine and Symptom Cluster
| Article | Year |
|---|---|
Clinical implications of CURE and PCI-CURE in patients with the acute coronary syndrome without persistent ST-elevation.
Topics: Acute Disease; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Electrocardiography; Heparin, | 2002 |
Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study.
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platelet A | 2003 |
Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents.
Topics: Acute Disease; Angina, Unstable; Clopidogrel; Emergency Medical Services; Fibrinolytic Agents; Hemor | 2003 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Ant | 2003 |
Current management of non-ST-segment-elevation acute coronary syndrome: reconciling the results of randomized controlled trials.
Topics: Anticoagulants; Clopidogrel; Coronary Disease; Echocardiography, Stress; Heparin, Low-Molecular-Weig | 2003 |
Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Corona | 2004 |
Acute coronary syndromes in women: is treatment different? Should it be?
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Female; Fibri | 2004 |
Clopidogrel in acute coronary syndrome: when, how much, how long?
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; D | 2005 |
CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Humans; Multicenter Studies as Topic; Myocardial Infar | 2005 |
[Secondary prevention of acute coronary syndromes: are we following correctly the guidelines?].
Topics: Acute Disease; Adrenergic beta-Antagonists; Algorithms; Angina, Unstable; Angiotensin-Converting Enz | 2006 |
[Anti-platelet drugs (aspirin, ticlopidine, etc)].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Humans; Meta-An | 2006 |
Percutaneous coronary intervention in a patient with von Willebrand's disease presenting with an acute coronary syndrome.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Coronary Angiography; Co | 2006 |
The year in non-ST-segment elevation acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Clopidogrel; Coronary Ve | 2006 |
[Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Eptifibatide; Fibrinolytic Agents; Humans; | 2006 |
[Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Thrombosis; Diabetes Complic | 2006 |
Platelet P2 receptors: old and new targets for antithrombotic drugs.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronar | 2007 |
Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Disea | 2006 |
Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial | 2007 |
Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Internati | 2007 |
Clopidogrel: who, when, and how?
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug A | 2007 |
[Malignant atrophic papulosis].
Topics: Biopsy; Combined Modality Therapy; Female; Humans; Intestinal Obstruction; Intestinal Perforation; J | 1994 |
Tufted angioma associated with platelet trapping syndrome: response to aspirin.
Topics: Aspirin; Biopsy; Blood Platelet Disorders; Child, Preschool; Combined Modality Therapy; Drug Therapy | 1997 |
[Intervention therapy of acute coronary syndrome].
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; | 1999 |
[Therapeutic inhibition of platelets in a acute coronary syndrome and in coronary intervention: mechanisms and clinical results].
Topics: Abciximab; Acute Disease; Adult; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; | 2000 |
The future of antiplatelet therapy: optimizing management in patients with acute coronary syndrome.
Topics: Angina, Unstable; Clopidogrel; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregat | 2000 |
[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].
Topics: Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Angina, Unstable; Anticoagulants; | 2001 |
[Role of clopidogrel in acute coronary syndromes without ST-segment elevation].
Topics: Acute Disease; Administration, Oral; Clopidogrel; Coronary Disease; Electrocardiography; Humans; Inf | 2002 |
17 trials available for ticlopidine and Symptom Cluster
| Article | Year |
|---|---|
Primary thrombophilia in México X: a prospective study of the treatment of the sticky platelet syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelet Disorders; Child; Clopidogrel; F | 2015 |
Early and late effects of clopidogrel in patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combinatio | 2003 |
[Non ST elevation acute coronary syndrome. Parameters of fibrinolysis during short term use of ticlopidine or clopidogrel].
Topics: Acute Disease; Adult; Antithrombins; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combinati | 2003 |
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin | 2003 |
[Non ST elevation acute coronary syndrome. Some characteristics of coagulation and von Willebrand factor during short term use of ticlopidine or clopidogrel].
Topics: Acute Disease; Adult; Angina, Unstable; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Dat | 2003 |
[Dysaggregants effect of platelet aggregation in patients with non-ST segment elevation acute coronary syndrome].
Topics: Acute Disease; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Electrocardiography; Female; | 2004 |
Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Electrocardiography; Fema | 2005 |
Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea
Topics: Abciximab; Acute Disease; Aged; Angina, Unstable; Antibodies, Monoclonal; Clopidogrel; Creatine Kina | 2005 |
Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Antithrombin III; Clopidogrel; Heparin; Humans; Myo | 2005 |
Aspirin, warfarin and a thienopyridine for acute coronary syndromes.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Hematologic Agents; Human | 2006 |
[Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome].
Topics: Anticoagulants; Aspirin; Clopidogrel; Electrocardiography; Enoxaparin; Fibrinolysis; Fibrinolytic Ag | 2005 |
High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Th | 2006 |
Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; C-Reactive Protein; CD40 Ligand; Clopidogrel; Dose-R | 2006 |
[Effectiveness and safety of clopidogrel bisulfate in complex therapy of patients with acute coronary syndrome with ST segment elevation].
Topics: Acute Disease; Angina Pectoris, Variant; Clopidogrel; Echocardiography; Female; Humans; Male; Middle | 2006 |
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Dose-Response Re | 2006 |
Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopi | 2007 |
Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.
Topics: Aged; Angina, Unstable; Clopidogrel; Coronary Disease; Creatinine; Double-Blind Method; Female; Glom | 2007 |
50 other studies available for ticlopidine and Symptom Cluster
| Article | Year |
|---|---|
An Extraordinary Case Associated with an Allergic Reaction to Clopidogrel: Coronary Artery Spasm or Kounis Syndrome?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Vasospasm; Drug Hypersensitivity; Humans; Male; Middl | 2015 |
Insulin autoimmune syndrome during the administration of clopidogrel.
Topics: Aged; Aged, 80 and over; Autoantibodies; Autoimmune Diseases; Blood Glucose; Clopidogrel; Glycated H | 2016 |
Life-threatening Wunderlich's syndrome with concurrent clopidogrel use.
Topics: Acute Kidney Injury; Blood Transfusion; Clopidogrel; Embolization, Therapeutic; Hemorrhage; Humans; | 2016 |
[Resistance to antiplatelet drugs in patients with non ST elevation acute coronary syndrome].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Disease; Drug Resistan | 2008 |
Cardiorenal syndromes--recommendations from clinical practice guidelines: the cardiologist's view.
Topics: Acute Disease; Acute Kidney Injury; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhib | 2010 |
Iliac vein compression syndrome: an underdiagnosed cause of lower extremity deep venous thrombosis.
Topics: Anticoagulants; Clopidogrel; Constriction, Pathologic; Heparin; Humans; Iliac Vein; Lower Extremity; | 2010 |
Aborted myocardial infarction in a patient with rapid progression of Wellens syndrome.
Topics: Aspirin; Clopidogrel; Coronary Stenosis; Early Diagnosis; Electrocardiography; Humans; Male; Middle | 2012 |
Reversible cerebral vasoconstriction syndrome and bilateral vertebral artery dissection presenting in a patient after cesarean section.
Topics: Aspirin; Cerebral Angiography; Cesarean Section; Clopidogrel; Female; Headache; Humans; Magnetic Res | 2013 |
[In acute coronary syndrome. Seize platelets with pliers].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2002 |
Pharmacological treatment of acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clopidogrel; Humans; Myocardial Infarction; | 2003 |
[Clearly superior in acute coronary syndrome. Helps aggressive platelet inhibition even after stroke?].
Topics: Acute Disease; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; My | 2003 |
Acute coronary syndrome associated with coronary aneurysm: a case report.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Coronary Aneurysm; Cor | 2003 |
Clopidogrel before urgent coronary artery bypass graft.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Art | 2003 |
Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.
Topics: Acute Disease; Aged; Atorvastatin; Clopidogrel; Comorbidity; Coronary Disease; Drug Interactions; Dr | 2003 |
[Dual platelet inhibition with clopidogrel and ASS. Who profits from the combination?].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2003 |
Serum sickness-like reaction associated with clopidogrel.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Humans; Male; Middle Aged; Platelet Aggregation Inhibi | 2003 |
[Guidelines: acute coronary syndrome (ACS)].
Topics: Acute Disease; Angina, Unstable; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Electr | 2004 |
[Interview with Prof. Dr. H. J. Rupprecht about secondary prevention: what is the optimal thrombocyte function inhibition?].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Long-Term Care; Myocardia | 2004 |
Oral clopidogrel load in aspirin-resistant capsular warning syndrome.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female | 2005 |
Clopidogrel-induced hypersensitivity syndrome associated with febrile pancytopenia.
Topics: Administration, Oral; Clopidogrel; Drug Eruptions; Erythema; Fever; Humans; Male; Middle Aged; Pancy | 2005 |
Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Drug Hypersensitivity; Female; | 2005 |
Evolving role of clopidogrel in acute coronary syndromes.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Syndrome; Tic | 2005 |
Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Ana | 2006 |
Drawbacks of nonrandomized trials in acute coronary syndromes.
Topics: Angina, Unstable; Cardiac Catheterization; Clinical Trials as Topic; Clopidogrel; Coronary Angiograp | 2006 |
Variable therapeutic effectiveness of clopidogrel in acute coronary syndromes.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Disea | 2006 |
[Inhibition of platelet aggregation for the secondary prevention after ACS: when clopidogrel instead of ASA, when clopidogrel and ASA?].
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Synd | 2006 |
High postclopidogrel platelet reactivity in non-ST-elevation acute coronary syndrome treated with stenting: a clue for adverse prognosis?
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Disea | 2006 |
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agen | 2006 |
Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge.
Topics: Aged; Angina, Unstable; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plate | 2006 |
The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart A
Topics: Aged; Angina, Unstable; Body Mass Index; Clopidogrel; Female; Guideline Adherence; Humans; Hypolipid | 2006 |
Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery.
Topics: Aged; Angina, Unstable; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Female; Guideline Ad | 2006 |
[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Coronary | 2006 |
Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aspirin; Clopidogrel; Coronary Disease; Diabetes Complic | 2006 |
[Beneficial effect of a loading dose of 600 mg of clopidogrel on platelet parameters in patients admitted for acute coronary syndrome].
Topics: Acute Disease; Angina, Unstable; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarcti | 2006 |
Clopidogrel in patients with acute coronary syndromes: learning from clinical practice.
Topics: Aged; Angina, Unstable; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plate | 2006 |
A cost analysis in patients with acute coronary syndrome using clopidogrel in addition to aspirin in a Hong Kong public hospital.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Costs and Cost Analysis; Female; Hong Kong; Humans; Ma | 2006 |
High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Fe | 2007 |
Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2007 |
[Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Blood Proteins; Cell Adhesion Molecules; Clop | 2007 |
Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative.
Topics: Acute Disease; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Dise | 2007 |
Very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment after percutaneous coronary intervention.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Clopidogrel; Coronary Angiogra | 2007 |
Dual antiplatelet agent failure: a new syndrome or clinical nonentity?
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Hum | 2007 |
May-Thurner syndrome in a pediatric renal transplant recipient--case report and literature review.
Topics: Adolescent; Clopidogrel; Creatinine; Edema; Female; Graft Survival; Humans; Iliac Vein; Kidney Disea | 2008 |
[Kasabach-Merritt syndrome. Intraoperative heparin therapy with follow-up combination therapy of heparin and ticlopidine for the control of intravascular coagulation].
Topics: Abdominal Neoplasms; Adult; Afibrinogenemia; Blood Coagulation Tests; Disseminated Intravascular Coa | 1993 |
-Neonatal Kasabach-Merritt syndrome healed by complete surgical excision of the angioma-.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Back; Glucocorticoids; Hemangioma; Humans; Infant, | 1998 |
Susac's syndrome: beneficial effects of corticosteroid therapy in a Japanese case.
Topics: Adult; Anti-Inflammatory Agents; Asian People; Asthma; Ataxia; Brain; Cognition Disorders; Confusion | 2001 |
[Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hu | 2001 |
[Clopidrogel in Acute Coronary Syndromes with Non-ST Elevation].
Topics: Acute Disease; Clopidogrel; Coronary Disease; Electrocardiography; Humans; Platelet Aggregation Inhi | 2002 |
The CURE trial: using clopidogrel in acute coronary syndromes without ST-segment elevation.
Topics: Angina Pectoris; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Random | 2002 |
[Kasabach-Merritt syndrome in children].
Topics: Aspirin; Child, Preschool; Disseminated Intravascular Coagulation; Embolization, Therapeutic; Hemang | 1992 |